Good Place. Good Things. Good Time.

Opinion: STAT+: A 10-point plan for sustaining the biopharma

Opinion: STAT+: A 10-point plan for sustaining the biopharma - AdobeStock 320657116

Covid-19 has underscored the critical role the biopharma industrial base plays in the U.S.’s national and economic security. As I write this, safe and effective Covid-19 vaccines that were developed in record time are protecting and saving lives and making it possible for people to return to the office, school, and travel — normal life, in other words.

In January 2018, STAT reporter Helen Branswell wrote a story that posed a worrisome question: “Who will answer the call in the next outbreak?” She recognized the risk to fragile partnerships between U.S. government agencies and the biopharmaceutical companies that had answered the call to a series of outbreaks, epidemics, and pandemics over a 15-year period, including West Nile, severe acute respiratory syndrome (SARS), the H1N1 pandemic, Middle East respiratory syndrome (MERS), H7N9 influenza, Ebola virus disease, and Zika.

Continue to STAT+ to read the full story…

Search more articles here: Opinion: STAT+: A 10-point plan for sustaining the biopharma

Read original article here: Opinion: STAT+: A 10-point plan for sustaining the biopharma



Disclaimers and Denial of responsibility..!

Denial of responsibility! TheTopMag.com is an automatic aggregator of all media around the world. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – jamesonline999@gmail.com . The content will be deleted within 72 hours.
You might also like
Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.